Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVSEF) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to $3.6 billion.

  • Novartis Ag's Cost of Revenue rose 863.42% to $3.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $13.7 billion, marking a year-over-year increase of 679.82%. This contributed to the annual value of $13.7 billion for FY2025, which is 679.82% up from last year.
  • Per Novartis Ag's latest filing, its Cost of Revenue stood at $3.6 billion for Q4 2025, which was up 863.42% from $3.5 billion recorded in Q3 2025.
  • Over the past 5 years, Novartis Ag's Cost of Revenue peaked at $4.0 billion during Q1 2021, and registered a low of $2.9 billion during Q3 2022.
  • In the last 5 years, Novartis Ag's Cost of Revenue had a median value of $3.3 billion in 2024 and averaged $3.4 billion.
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 1414.41% in 2021, then crashed by 2701.88% in 2022.
  • Novartis Ag's Cost of Revenue (Quarter) stood at $4.0 billion in 2021, then fell by 23.52% to $3.0 billion in 2022, then decreased by 0.62% to $3.0 billion in 2023, then rose by 9.99% to $3.3 billion in 2024, then grew by 8.63% to $3.6 billion in 2025.
  • Its Cost of Revenue stands at $3.6 billion for Q4 2025, versus $3.5 billion for Q3 2025 and $3.3 billion for Q2 2025.